Pharmacogenomics and the Most Commonly Prescribed Drugs of 2011

DECEMBER 21, 2012
David F. Kisor, BS, PharmD, RPh; Caitlin Munro, PharmD Candidate; and Emily Loudermilk, PharmD Candidate
Pharmacogenomics and the Most Commonly Prescribed Drugs of 2011
 
David F. Kisor, BS, PharmD, RPh
Professor of Pharmacokinetics
Chair of the Department of Pharmaceutical and Biomedical Sciences
Raabe College of Pharmacy, Ohio Northern University
Ada, Ohio
 
Caitlin Munro, PharmD Candidate
Raabe College of Pharmacy, Ohio Northern University
Ada, Ohio
 
Emily Loudermilk, PharmD Candidate
Raabe College of Pharmacy, Ohio Northern University
Ada, Ohio
 

 
Disclosures
 
The following contributors have no relevant financial relationships with commercial interests to disclose:
 
Faculty: David F. Kisor, BS, PharmD, RPh; Caitlin Munro, PharmD Candidate; and Emily Loudermilk, PharmD Candidate
 
Pharmacy Times Office of Continuing Professional Education (PTOCPE): Judy V. Lum, MPA; Ann C. Lichti, CCMEP; and Elena Beyzarov, PharmD
 
Pharmacy Times Editorial Staff: Jennifer Whartenby and David Allikas
 
PTOCPE uses an anonymous peer reviewer as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.
 

 
Educational Objectives
 
Upon completion of this educational activity, participants should be able to:
  1. Identify those agents among most commonly prescribed drugs of 2011 that include genomic biomarker information within product labeling and FDA resources.
  2. Describe the context of the biomarker related to the specific drug.
  3. Identify the biomarker–drug relationships that impact drug dosing.
  4. Describe biomarker–drug relationships relative to pharmacokinetics and/or pharmacodynamics and understand their limitations.
Type of activity: Knowledge
Release date: December 10, 2012
Expiration date: December 10, 2014
Estimated time to complete activity: 2 hours
Fee: This lesson is free online
 
Click here to view this activity.

SHARE THIS SHARE THIS
0
 

In Seniors: Consider CMV Serostatus
When Recommending Flu Vaccine

Older people who have cytomegalovirus seem to have less robust responses to the trivalent influenza vaccine than those who do not have CMV.


 

 

Conference Coverage
News from the year's biggest meetings


Pharmacist Education
Clinical features with downloadable PDFs


 

SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.